Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares China Large-Cap ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B). The key difference: iShares China Large-Cap ETF is far larger — about 5.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares China Large-Cap ETF for 150 Days on average.
| DNA | FXI | |
|---|---|---|
Market Cap | $763.64M | $3.86B |
Volume | 3,204,177 | 16,323,837 |
Sector | Health | — |
52-Week High | $15.83 | $41.08 |
52-Week Low | $5.48 | $31.59 |
Typical Hold Time | 7 Days | 150 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
